Cargando…
Absolute Oral Bioavailability of Glasdegib (PF‐04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers
Glasdegib (PF‐04449913) is an oral small‐molecule inhibitor of the Hedgehog signaling pathway under development for treating myeloid malignancies. This was an open‐label phase 1, randomized, 2‐sequence, 2‐treatment, 2‐period, crossover study evaluating the absolute bioavailability of glasdegib in he...
Autores principales: | Shaik, Naveed, Hee, Brian, Liang, Yali, LaBadie, Robert Roland |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850403/ https://www.ncbi.nlm.nih.gov/pubmed/30977980 http://dx.doi.org/10.1002/cpdd.692 |
Ejemplares similares
-
Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study
por: Shaik, Naveed, et al.
Publicado: (2018) -
Phase I study of glasdegib (PF‐04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies
por: Minami, Yosuke, et al.
Publicado: (2017) -
Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers
por: Shaik, Naveed, et al.
Publicado: (2021) -
The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells
por: Giordani, Giorgia, et al.
Publicado: (2016) -
Clinical and Model‐Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study
por: Masters, Joanna C., et al.
Publicado: (2020)